Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation...

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Refractory Status Epilepticus (RSE) is a severe neurological emergency with high morbidity and mortality.
• Neuroinflammation is increasingly recognized as a key mechanism in RSE pathogenesis.
• Current evidence for RSE treatments, including immunotherapies, is limited, hindering optimal patient care.

Purpose of the Study:

• To review the role of immunotherapy in treating RSE.
• To highlight the potential efficacy of agents like Tocilizumab in RSE.
• To explore innovative clinical trial designs for evaluating RSE interventions.

Main Methods:

• Literature review focusing on immunotherapy and neuroinflammation in RSE.
• Case series analysis of Tocilizumab in RSE patients.
• Discussion of adaptive platform trials for RSE research.

Main Results:

• Immunotherapy presents a promising avenue for RSE treatment by targeting neuroinflammatory pathways.
• A case series suggests potential efficacy of Tocilizumab in managing RSE.
• Traditional trial designs are insufficient for the heterogeneity of RSE.

Conclusions:

• Targeting neuroinflammation via immunotherapy offers a potential therapeutic strategy for RSE.
• Adaptive platform trials are crucial for generating robust evidence efficiently.
• Innovative trial designs are needed to accelerate the evaluation of novel RSE treatments.